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Naturally occurring polymers are promising biocompatible materials that have many applications 
for emerging therapies, drug delivery systems and diagnostic agents. The handling and 
processing of such materials still constitutes a major challenge which can limit the full 
exploitation of their properties. This study explores an ambient environment processing 
technique: coaxial electrospray (CO-ES) to encapsulate genistein (an isoflavonoid and model 
drug), superparamagnetic iron oxide nanoparticles (SPIONs, 10-15 nm) and a fluorophore 
(BODIPY) into a layered (triglyceride tristearin shell) particulate system, with a view to 
constructing a theranostic agent. Mode mapping of CO-ES led to an optimized atomization 
engineering window for stable jetting, leading to encapsulation of SPIONs within particles of 
diameter 0.65 - 1.2 µm and drug encapsulation efficiencies of around 92%. Electron Microscopy 
was used to image the encapsulated SPIONs and confirm core-shell triglyceride encapsulation in 
addition to further physicochemical characterization (AFM, FTIR, DSC and TGA). Cell viability 
assays (MTT, HeLa cells) were used to determine optimal SPIONs loaded particles (~1 mg/mL) 
while in vitro release profile experiments (PBS, pH = 7.4) demonstrate a triphasic release profile. 
Further cell studies confirmed cell uptake and internalization at selected time points (t = 1, 2 and 
4 h). The results suggest potential for using the CO-ES technique as an efficient way to 
encapsulate SPIONs together with sensitive drugs for the development of multi-modal particles 
that have potential application for combined imaging and therapy. 
 





Advances in nanotechnology continue to have a tremendous impact on medicine.  In particular, 
new approaches for targeted drug delivery and biomedical imaging sciences have benefited from 








 NPs for medical use 
are typically composed of an inorganic or organic matrix material that is functionalized with a 
drug and/or a targeting agent.  Superparamagnetic iron oxide nanoparticles (SPIONs) have been 
widely investigated as contrast agents for magnetic resonance imaging (MRI) due to their ability 







 External magnetic fields can also be used to guide these nanoparticles 
to targets within the body and then used to induce local hyperthermia to destroy cells. Their low 
toxicity coupled with their ease of synthesis also makes them highly attractive for such 
therapeutic and diagnostic applications. The nanostructure of SPIONs is typically based on an 
inorganic maghemite (-Fe2O3) and/or magnetite (Fe3O4) core, and can vary in size from 2 nm to 
microns depending on the synthesis method. The high surface-to-volume ratio of SPIONs 
typically result in aggregation, hence, coating with a suitable biocompatible materials is 
necessary to ensure discrete particle formation. Hydrophilic polymers such as polyethylene-
glycol (PEG), PEG/polyethylenimine co-polymers, dextran or chitosan are often used to inhibit 
aggregation and to ensure water solubility. Functionalizing the shell of NPs is also an important 
strategy for improving targeting ability, drug encapsulation and controlled release. There are a 
number of techniques to encapsulate targeting molecules and drugs onto nanoparticles; these 
include various bioconjugation methods, electrostatic interactions, co-loading of drugs into the 
polymer shell matrix and adsorption into hollow or mesoporous structures.
9
 Several recent 
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examples of drug loaded SPIONs have shown excellent targeting efficiencies and anticancer 











The protection afforded to the NP carrier matrix can lead to the more selective delivery of 
active components, enhance drug efficacy and reduce toxicity.
15
 Tristearin is a lipid commonly 
used to prepare solid-lipid nanoparticles (SLNs) for the development of drug delivery carriers. 
SLNs are biocompatible, biodegradable and physico-chemically stable with a low toxicity. They 







 Recently, the encapsulation of aloe-emodin (AE) in SLNs, using a high-pressure 
homogenization technique, has been demonstrated to improve its anti-cancer efficacy.
19
 AE has 
poor water solubility, low absorption and bioavailability issues which has limited its clinical 
applications. AE-SLNs showed much higher in vitro cytotoxicity against several human cancer 
lines compared to AE solutions alone, the improved efficacy was attributed to the increased 
cellular uptake of AE as a result of the SLN formulation.  
Consistent and reproducible control over drug loading and particle size are still challenging, 
hence, new methods that are better able to provide this control and can be generally applied to a 
range of particle types and drug molecules are highly sought after. Electrohydrodynamic 
atomization (EHDA) (or electrospray) involves the application of an electric field to a flowing 
electrically conductive liquid (or co-flow system) in order to generate micro- or nano-sized 
particles; it is finding increasing numbers of applications for emerging pharmaceutical 
technologies.
20
 This technique has been demonstrated by some of us in a variety of novel 
biomedical applications.
21–23
 Herein, we report the use of a coaxial electrospray (CO-ES) 
technique to generate multi-modal submicron-to-micron sized particles combining an SPION 
core with an optical probe integrated into a tristearin shell.  A model drug compound (genistein) 
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was also encapsulated into a core-shell material using this electrospray technique and the drug 
release profile, and cellular uptake of the particles investigated.  
 
MATERIALS AND METHODS 
Chemicals and Reagents.  Tristearin (≥ 99%, MW 891.48 g/mol) and PEG (MW 20000 g/mol) 
were purchased from Sigma-Aldrich, Dorset, UK. Genistein (≥ 98% purity, Mw=270.24 g/mol, 
crystal powder form) was purchased from VWR International Ltd, Leighton Buzzard, UK. 
SPIONs
24
 and boron-dipyrromethene (BODIPY) fluorescent dye
25
 were synthesized using 
methods based on literature protocols. 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan 
(MTT, Thiazolyl blue formazan), FeCl2 (98%), FeCl3 (97%), NH4OH (Ammonium hydroxide 
solution/ ACS reagent 28.0-30.0% NH3 basis) and oleic acid (≥ 99%) were all purchased from 
Sigma-Aldrich, Dorset, UK. Solvents were obtained from commercial sources and used as 
received without additional purification. 
Synthesis of Superparamagnetic Iron Oxide Nanoparticles (SPIONs).  Iron(II) chloride (0.63 
g, 5.0 mmol) was dissolved in HCl (2.5 mL, 5.0 mmol) to give a 2 M yellow solution. Iron(III) 
chloride (1.62 g, 10.0 mmol) was dissolved in deoxygenated water (10 mL) to give a 1 M orange 
solution. The solutions were mixed together and added to a 0.7 M ammonium hydroxide solution 
(125 mL, 87.5 mmol). The mixture was then stirred vigorously for 30 min. The resulting black 
precipitate was separated magnetically (0.80 g, 70%). The capping agent, oleic acid (1.6 mL, 5.0 
mmol) was dissolved in acetone (5 mL), and added drop-wise to the separated black precipitate 
and the mixture was then heated at 80 °C for 30 min and the resulting precipitate separated 
magnetically again, and washed with acetone and then dissolved in 50 mL of toluene. The 
resulting solution was centrifuged at 4000 rpm for 1 h to separate any precipitates and the 
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supernatant liquid was collected and then evaporated to dryness to give the SPIONs
26
 
(Supporting Information, Figure S1). 
Preparation of Electrospray Solutions.  A series of solutions were prepared for the 
electrospray (ES) process. Tristearin was dissolved in dichloromethane (2 w/v %) through 
mechanical stirring at ambient temperature (22 °C). PEG was added to ethanol (5 w/v %) and 
stirred vigorously for 30 min. Genistein was then dissolved (1 mg / mL) in the PEG solution with 
mechanical stirring for 30 min. The synthesized SPIONs were suspended in the final solution 
and sonicated for 5 min. 
Characterization of Electrospray Solutions.  The electrospray solutions were characterized for 
density, surface tension, viscosity and electrical conductivity. Density values were obtained 
using standard 25 mL pycnometers (VWR, Leicestershire, UK). The surface tension of the 
solutions was measured using a 0/80256E Balance Tensiometer (White Elec. Inst. Co., Ltd., 
Worcestershire, UK) using the Du Noüy platinum ring technique. The solution viscosities were 
measured using a SV-10 Sine-wave Vibro-Viscometer (A&D, Oxford shire, UK). A FG3-
FIVEGO conductivity meter (Mettler Toledo, Leicester, UK) was used to measure the electrical 
conductivity of the solutions. The mean value of five consecutive readings was used in all cases.   
Encapsulation of SPIONs.  The coaxial electrospraying device consists of two concentrically 
aligned stainless steel capillary needles with outer diameters of 0.9 and 1.9 mm, respectively. 
The needle was connected to a high voltage supply (up to 30 kV, 1.5 mA, Glassman High 
Voltage Supply, UK). The solutions were perfused using a syringe pump (World Precision 
Instruments, Florida, US). The deposition distance for the encapsulation of SPIONs and 
genistein was kept at 100 mm from the tip of the needle to the collection substrate and the 
samples were collected in a glass vial (15 mL of deionized water). The experiments were carried 
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out at ambient temperature (22 °C). The single needle and coaxial electrospraying set-up are 
shown in Figure 1. 
 
Figure 1. Schematic of electrospray set-up (A) the single needle and coaxial electrospraying devices (B) 
close-up image of the atomization process (stable cone-jet mode) and (C) key materials used. 
 
Jetting and Mode Mapping.  Jetting and mode mapping were studied to optimize the EHDA 
process. For this, four individual processing materials were studied which included the optimized 
formulation, a suspension containing SPIONs and a PEG/ethanol solution. The mode mapping 
procedure involves assessment of the jetting mode at incremental changes to flow rate and 
applied voltage. It was anticipated that there would be an impact on jet formation as a result of 
changes in electrical conductivity and surface tension due the presence of SPIONs.  To ensure 
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optimum jetting behavior, a camera (Samsung NX 2000, 21.6 MP/APS-C sensor, Korea) was 
used to capture digital images of jetting modes. 
Spectral and Thermal Characterization.  Differential scanning calorimetry (DSC) analysis of 
the samples (raw materials and encapsulated particles) was carried out using a Jade DSC 
PerkinElmer 204 F1 Phoenix (Netzsch, Selb, Germany) instrument at a heating rate of 10 °C / 
min under a nitrogen purge of 70 mL / min from 20 to 300 °C. The physical properties of the 
samples were also characterized by thermogravimetric analysis (TGA) using a PerkinElmer-
Thermogravimetric analyzer (Pyris, Germany). Fourier transform infrared (FTIR) spectra of raw 
materials and encapsulated SPIONs were recorded using a PerkinElmer (Analytical Siemens, 
USA) with a resolution of 2 cm
-1
. The spectra were recorded between 4000 and 650 cm
-1 
after 
correction of the baseline.  
Electron Microscopy Analysis and Zeta-Potential Measurement.  Scanning electron 
microscopy (SEM) was carried out using a Zeiss-EVO LS 15 instrument (Germany), operated at 
an accelerating voltage of 10 kV to study the size and surface morphology of the particles. 
Samples were gold coated using a rotary-pumped sputter coater (Q150R ES, Quorum 
Technologies Ltd, East Sussex, UK) to improve the conductivity of the surface of the sample and 
to prevent overcharging. Transmission electron microscopy (TEM) was performed using a JEOL 
TEM 2100F (JEOL Ltd, Japan) instrument with an operating voltage of 200 kV. Atomic force 
microscopy (AFM) measurements were performed using a Park AFM XE-100 series scanning 
probe microscope. All images were taken in True non-contact mode with a scan rate of 0.5 Hz at 
room temperature and pressure using a commercial silicon cantilever (Innovative Solutions, 
Bulgaria). No modifications were made to the samples prior to imaging. All processing and 
analysis of the data was undertaken using the Park AFM XEI software. The particle size and size 
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distribution of the particles were measured by Carl Zeiss SmartTiffV3 software. These 
measurements were performed in triplicate. Zeta-potential (ζ-potential) studies for core-shell 
encapsulated nanoparticles and blank tristearin particles were performed using a Nanobrook 
Omni analyser (Nanobrook Omni, Brookhaven, US). The mean ± standard deviation of ten 
replicates was obtained. Particles were analysed in phosphate buffered saline (PBS, pH = 7.4). 
 
Drug Encapsulation and Release Study.  The genistein loading in the tristearin particles was 
calculated based on equation 1.   
Encapsulation efficiency (EE) = 
            (1) 
 (Equation 1) 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 −  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔
× 100  
  
Two types of genistein formulation were evaluated for release kinetics. These were a 
composite tristearin / SPIONs (single-needle electrospray) combination and a final encapsulation 
formulation (coaxial electrospray / CO-ES). In the latter case, a known quantity of genistein-
loaded particles was dissolved in ethanol under mechanical stirring for 2 h and a UV-vis 
spectrophotometer (λ = 260 nm) and was used to determine the concentration of the drug in the 
final formulation. The theoretical value was calculated based on the infusion of a known 
concentration of the final formulation of material.  
For release studies 1 mL of formulation was electrosprayed directly into 10 mL of PBS (pH = 
7.4) using the CO-ES technique. The same process was carried out for the composite tristearin / 
SPIONs composition using single-needle electrospray. The concentration of genistein in the 
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formulation was 1 mg/mL. Once electrospraying (ES) process was completed, the particles 
release medium mixture is placed into a shaking water bath at 37 °C (Stuart SB 540, UK). At 
defined time intervals, the PBS-particle mixture was removed and centrifuged (Eppendorf, 
centrifuge 5702, Germany) at 1000 rpm for 5 min. A pipette was used to remove 1 mL for UV 
measurement. Fresh PBS medium (1 mL) was added to the existing PBS-particle solutions 
before returning them to the water bath. The release of genistein was carried out over a 30 h 
period in triplicate. For active release in vitro studies the number of replicates was 3 (n=3). 
Cell Culture.  To assess the potential biocompatibility of the encapsulated SPIONs, the HeLa 
cell line was used.
27
 HeLa cells were cultured in Dulbecco’s Modified Eagle Medium, 
supplemented with 10 % fetal calf serum, 1 % non-essential amino acids, L-ascorbic acid (0.150 
g/L), 2 mM L-glutamine, 0.02 M HEPES, penicillin (100 units/mL) and streptomycin (0.1 
mg/mL) (all purchased from Sigma, Dorset, UK). HeLa cells were maintained at 37 °C in a 
humidified incubator with 5 % CO2. 
MTT Cytotoxicity Assay.  HeLa cells were seeded at 1 × 10
5 
cells per well using a 96 well plate 
(Nunc, Fisher Scientific, Loughborough, UK) and were incubated for 24 h in culture media. 100 
µL of the encapsulated SPIONs (CO-ES) and electrosprayed tristearin NPs (single-needle 
electrospray) were added to selected wells at concentrations of 0.1, 0.25, 0.5, and 1 mg / mL. The 
cells were further incubated for 24 h and then 50 µL of MTT reagent (prepared in a physiological 
solution) were then added to cells and incubated for 2 h according to the manufacturer’s 
instructions. The negative control contained media only. After 2 h of MTT incubation, the 
culture media was removed and cells were washed with 100 µL of PBS prior to the addition of 
100 µL of dimethyl sulfoxide (DMSO) to each well to dissolve formazan precipitates. The 
quantity of formazan, which is proportional to the number of viable cells, was measured via the 
11 
 
change in absorbance at 570 nm using a SpectraMax M2e Multimode Microplate Reader with 
SoftMax Pro Software (Molecular Devices, VWR, West Sussex, UK). 
T2 Relaxivity measurements.  Relaxivity measurements at a magnetic field of 9.4 T (400 MHz) 
were performed in a NMR spectrometer (Bruker AV400, Germany) at room temperature with a 
standard Carr Purcell Meiboom Gill (CPMG) sequence. The relaxivity constant (r2) was 
calculated from the slope of the curve obtained by fitting the (T2)
-1
 values versus the total Fe 
concentration in mM of encapsulated SPIONs (0, 0.54, 1.1, 2.15, 4.31 mM).  
Confocal Imaging and Cellular Uptake.  Confocal microscopy was performed on a CF4 - 
Leica SP5 inverted confocal microscope (Leica, Germany) with a tuneable infrared laser for 
multiphoton imaging, motorized stage and full incubation chamber. Cell suspensions were 
prepared at a concentration of 1 × 10
4
 cells per well and seeded to 6 well plates (Nunc, Fisher 
Scientific, Loughborough, UK), each containing an autoclaved 13 mm cover slip. After 24 h of 
incubation, 100 μL of encapsulated SPIONs (1 mg/mL) were added to each of the wells at 
different time points (1, 2, and 4 h) and incubated for another 24 h. After 24 h, the media were 
removed and the cells were washed with PBS twice and then fixed using Alfa Aesar 
Paraformaldehyde, 4% in PBS paraformaldehyde (Fisher Scientific, Loughborough, UK). A drop 
of AF1 Citifluor antifadent mountant (Agar Scientific Ltd, Essex, UK) was added to a 
microscope slide and the coverslip placed on it, (cell side down) prior to microscopy.  
Statistical Analysis.  The data from MTT cytotoxicity assay were analyzed statistically using 
one-way ANOVA with Bonferroni post hoc test; P <0.05 was considered as statistically 
significant. The criterion for statistical difference between groups was P <0.05. The statistical 






RESULTS AND DISCUSSION 
Synthesis of SPIONs.  Superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized 
using the method described by Feng et al.
26
 The SPIONs possessed a mean size range of 10-15 
nm as determined by TEM. UV-vis spectroscopy further confirmed the synthesis of SPIONs
28
 
(Supporting Information, Figure S2).  
Excipient Suitability. Formulation of excipient media used for particle engineering have been 
explored for numerous in vitro and in vivo studies. For example, genistein has been explored for 
chemotherapeutic applications and is known to be an excellent molecule for several other 
biological functions.
29
 Similarly, tristearin has been explored for numerous therapeutic dosage 
forms involving solid lipid nanoparticles
30
 and as solid oral drug delivery systems (e.g. tablets)
31
 
displaying good in vitro and in vivo outcomes. SPIONS have been investigated as non-toxic MRI 
imaging agents and theranostic agents. PEG is a widely-used excipient in pharmaceutical 
formulations while BODIPY has excellent optical properties for cellular imaging.   
Materials Characterization.  The physical properties of the materials important indicators for 
ES processing suitability.  The ES processing of solutions relies on the relationship of surface 
tension, density and electrical conductivity to determine jet formation and stability. During jet 
formation, the electrical force applied results in deformation of the liquid into a cone if the 
solution is sufficiently electrically conducting. Surface tension counteracts the action of the 
electric field enabling the formation of a stable cone jet. The applied electrical force must exceed 
the surface tension in order to generate a spray. Therefore, materials possessing a surface tension 
less than water (70 mN/m) are ideal for ES. All solutions in this study demonstrated electrical 
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conductivity values in suitable ranges for ES. Ethanol-based formulations have been used 
extensively in ES investigations,
32
 though dichloromethane, which has a lower electrical 
conductivity than ethanol, has also been employed for matrix type nanoparticle formulations.
33
 
The surface tension of all suspension and processing media used in this work were below 70 
mN/m in order to ensure their suitability for the ES process. All solutions demonstrated low 
viscosity when compared to previous studies used for electrospinning fibers.
22
 Viscosity is an 
important parameter as it is often used to determine the morphology of ES media. Most 
polymeric solutions with a high molecular weight will yield fibers. In this study, the low 
viscosities will ensure particle synthesis will result in preference to fiber formation. Table 1 
details the main physical properties of solutions and solvents used in this study.   
 
 
Table 1. Physical properties of the solutions and solvents. 
 
Jetting and Mode Mapping (Spraying Stability).  Based on the values (apply voltage vs. flow 
rate), all formulations were subjected to mode mapping and ES optimization. For the 
PEG/Ethanol formulation, the flow rate (1-45 µL/min) and applied voltage (0-30 kV) were 
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selected. A camera was used to provide continuous monitoring of the jetting behavior over time. 
The jetting behavior of the PEG/Ethanol solution is shown in the Supporting Information 
(Figure S3-A and Table S1-A) and follows a clear trend. When the flow rate is below 6.5 
µL/min, inconsistent results are observed, suggesting that the infusion is insufficient to force the 
medium out of the nozzle continuously. This affects the particle size, as the true flow rate is not 
observed. Consistent flow from the needle was observed with flow rates in the range 10-45 
µL/min, while values beyond this flow rate produced jetting instability. Between the applied 
voltages 12-24.1 kV and a flow rate of 10 to 45 µL/min, a stable jetting window was established. 
On either side of this applied voltage range (e.g. < 12 kV and > 24.1 kV), unstable jetting 
occurred. 
The jetting behavior of the PEG/ethanol/SPIONs formulation is shown in the Supporting 
Information (Figure S3-B and Table S1-B). Unlike previous formulations, the 
PEG/ethanol/SPIONs medium is more inconsistent even when the flow rate is set at 15 µL/min. 
Numerous articles have used flow rates in this region to form polymeric particles by ES 
methods.
34
 This increase in inconsistency is attributed to the presence of the SPIONs in the 
formulation. The SPIONs can agglomerate, which can lead to intermittent nozzle blockage and 
media flow and subsequently a greater flow rate (or a burst of increased flow), is required to 
maintain continuous media infusion. In general, this system (PEG/ethanol/SPIONs) is found to 
be unstable throughout the mapping process. For example, when continuous flow is achieved (> 
15 µL/min) at an applied voltage below 8 kV, only micro dripping is observed, which is a 
precursor to the stable jetting mode. However, when the applied voltage is increased above 8kV, 
unstable jetting is observed. This, again, is attributed to the effects of a non-homogenous 
medium (particle agglomeration).  
15 
 
The jetting behavior of the tristearin/dichloromethane formulation (SI, Figure S3-C and Table 
S1-C) was found to display inconsistent flow behavior at flow rates below 6.5 µL/min, 
suggesting insufficient infusion of material. By increasing the flow rate (6.6 - 12.5 µL/min), the 
dripping mode was again observed with jetting behavior. However, at flow rates of 12.5, 25 and 
50 µL/min and applied voltages of 7 - 18.8, 11.8 - 19.2 and 11 - 15.2 kV, respectively, a stable 
jetting window was established. An unstable jetting mode was observed either above or below 
these applied voltages. 
The final formulation using the coaxial electrospraying (CO-ES) process, consisting of 
tristearin (2 w/v %) in the outer needle and PEG/Ethanol (5 w/v %), genistein (1 mg/mL), 
SPIONs (0.5 w/v %), BODIPY (0.01 mg/mL) in the inner needle, is shown in Figure 2A and 
Table S1-D (Supporting Information). The flow rate in the inner needle was fixed at 20 µL/min. 
An inconsistent combined flow was observed for flow rates up to 19 µL/min and applied 
voltages in the range 1 - 30 kV. Dripping mode behavior of the coaxial process was observed 
when increasing the flow rate to ~ 40 µL/min with an applied voltage of 8 kV. However, when 
using the same flow rate and increasing the applied voltage to 30 kV, an unstable jetting window 
was observed. An operating window was thus established for stable jetting at 25, 27.5 - 33 and 
33 - 35.2 µL/min with applied voltages of 13, 15 and 12.5 kV, respectively. An uneven co-flow 
was observed at higher flow rates (40.2 - 50 µL/min). Figures 2B-F show the jetting modes of 
































Electrospray Encapsulation. The coaxial electrospray process is an emerging method to 
encapsulate bio-molecules and actives.  It demonstrates clear benefits over existing platforms.  
Firstly, the process is operational at the ambient temperature; permitting the encapsulation of 
sensitive molecules and active pharmaceutical ingredients (APIs).
34
 Secondly, the process is low 
shear and prepares several inter-particle compartments in a single engineering step; unlike 
several chemical techniques, which require the use of numerous solvents and medium transfer 
phases. In this regard, the technique has shown higher encapsulation efficiencies for 
biomolecules when compared to other techniques, as material loss is reduced in-between process 
steps. More recently, single nozzle techniques are being explored for scalability, which are 
showing promise. The process parameters are facile; providing morphological and size variation 
during engineering.
20
 Finally, since device size can be varied from a small handheld-set to 
multiple capillaries the underlying principle can fit into several product development settings.
35
 
Spectroscopic and Analytical Characterization of Electrosprayed Particles.  Fourier 
transform infrared (FTIR) spectroscopy provided evidence for the presence of iron oxide within 




 The spectra for the 
encapsulated SPIONs also show the presence of C-O absorptions for the PEG component in the 
region from 1097 to 1341 cm
-1
, while the band at 1468 cm
-1 
can be assigned to the C-H bending 
vibrations from the oleic acid chain.
38
 The vibrational band at 1736 cm
-1
 indicates the presence 
of tristearin (C=O stretch) in the encapsulated particles.
39
 The peaks at 2849 and 2914 cm
-1 
could 
be assigned to C-H stretches of the aliphatic chains.
37
 In addition, direct comparison of the FTIR 
spectra of the individual constituents (tristearin, PEG, SPIONs and genistein) against the 
encapsulated assembly confirms the presence of these components in the final formulation of the 
encapsulated SPIONs (SI, Figure S4 A-E). 
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Figure 3 shows the differential scanning calorimetric (DSC) and thermogravimetric (TGA) 
analysis data for the encapsulated SPIONs and parent SPIONs. For the SPIONs alone, the DSC 
curve exhibits no particular heat change or peak during scanning (Supporting Information, 
Figure S5-A) and the corresponding TGA curve displays a weight loss of 28 % between 126 to 
441 °C, which is attributed to the gasification of the small molecules present (e.g., water, oleic 
acid).
34
 The DSC curve of the tristearin and PEG indicate a crystallization event observed 
between 44-77 °C, which is attributed to their melting transitions
40
 (Supporting Information, 
Figure S5-B). The DSC of the encapsulated SPIONs (final formulation) reveals a crystallization 
peak between 47-76 °C but no notable heat change or crystallization observed for the final 
formulation. These results suggest the presence of intermolecular interaction between the 
materials within the encapsulated particles (Figure 3A). The TGA (Figure 3B) of the 
encapsulated SPIONs and parent SPIONs show gradual decomposition between 300-400 °C, 
reflecting the decomposition of the organic components in the outer layers of the SPIONs (oleic 
acid and solvent) encapsulated SPIONs (tristearin, PEG, genistein and BODIPY). From the TGA 
is can be seen that approximately 10 % wt. of the encapsulated SPIONs is inorganic iron oxide 



























Figure 3. Thermogravimetric analysis of SPIONs and encapsulated SPIONs: (A) DSC and (B) related 
TGA.  
 
Microscopy Analysis and Zeta-Potential.  To evaluate the size and morphology of the 
electrosprayed particles under stable conditions, SEM and TEM were used. Electron 
micrographs of tristearin nanoparticles (2 w/v %) using single needle ES at an operating voltage 
of 15 - 18.8 kV and flow rate of 12.5 µL/min shows spherical particles (Figure 4A-B). The 
particle size and size distribution of particles was measured using Carl Zeiss, SmartTiffV3 
software and the mean value of three data sets recorded. At least 50 particles were chosen 
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randomly from the SEM image (84 ± 20 nm, Figure 4J). Figure 4C-D show the generated 
composite tristearin-SPIONs [tristearin in dichloromethane (2 w/v %) and SPIONs (0.5 w/v %)] 
using the single needle ES process at an operating voltage of 16 - 19 kV and a flow rate of 25 
µL/min with an average particle size of 230 ± 41 nm (Figure 4K). However, less uniform and 
varied particle morphology is also apparent. 
For the final formulation, the CO-ES process was employed using tristearin (outer needle) and 
SPIONs, PEG, genistein and BODIPY (inner needle) to generate a more uniform particle 
formulation, as shown in Figure 4E and 4F (at higher magnification). Encapsulated SPIONs 
were generated with a mean size distribution of approximately 650 ± 30 to 1200 ± 60 nm 
(Figure 4L). The synthesized SPIONs, with average size between 10 - 15 nm (Figure 4G), were 
used for the final encapsulation formulation. To verify the SPIONs encapsulation in the final 
formulation (using CO-ES) and the composite tristearin-SPIONs (single-needle ES) material, 
TEM was used. Figure 4H shows the SPIONs, which are dispersed throughout the composite 
system. In addition, greater roughness of the surface is apparent, which is attributed to a matrix 
mixture of SPIONs and tristearin polymer.  
Sample I (Figure 4I) exhibits a well-defined core-shell structure, with SPIONs bound inside a 
smooth polymeric surface. The encapsulation of SPIONs within the outer layer (tristearin) is 
clearly visible from the change in contrast. The difference in shape is attributed to agglomerated 
SPIONs. In conventional electrospraying, where polymer and low molecular weight additives are 
used (e.g. drugs), the drying process is simple and the lowest energy conformation for particle 
formation is spherical. In this instance, we hypothesize that the small size of the particles and the 








Figure 4. Scanning and transmission electron microscopy (SEM, TEM) images showing tristearin NPs, 
composite tristearin & SPIONs and encapsulated SPIONs, (A) electron micrograph of tristearin NPs 
using single-needle ES at an operating voltage of 15 - 18.8 kV and flow rate of 12.5 μL/min, scale bar 
22 
 
1000 nm, (B) at higher magnification, scale bar 350 nm, (C) electron micrograph of composite tristearin-
SPIONs using single-needle ES at an operating voltage of 16 - 19 kV and flow rate of 25 μL/min, scale 
bar 20000 nm, (D) with higher magnification, scale bar 2000 nm, (E) electron micrograph of encapsulated 
SPIONs with tristearin (outer layer) and SPIONs, PEG, genistein, BODIPY in inner layer using CO-ES 
needles at an operating voltage of 15 kV and a flow rate of 20 and 25 μL/min for inner and outer needles 
respectively, scale bar 20000 nm, (F) at higher magnification, scale bar 2000 nm, (G) TEM image of 
synthesized SPIONs, scale bar 50 nm, (H) TEM image of composite tristearin-SPIONs (single-needle 
ES), scale bar 100 nm, (I) TEM image showing the encapsulated SPIONs with core-shell structures, scale 
bar 500 nm, (J-L) size distribution of tristearin NPs, composite tristearin-SPIONs and encapsulated 
SPIONs. 
 
Atomic force microscopy (AFM) reveals important surface topography characteristics of 
specific particle samples. Two samples were prepared for AFM analysis; a composite sample 
comprising SPIONs embedded in a tristearin polymeric matrix (Figure 5A) and the final 
encapsulation formulation comprising SPIONs with a tristearin core shell (Figure 5B). The size 
distribution for both samples correlates well with findings obtained from electron micrographs. 
There is also clear evidence of particle merging, or coalescence upon drying for both sample 
types. More interestingly, the surface roughness further supports the site-specific incorporation 
of magnetic nanoparticles.  The composite mixture possesses a greater roughness [roughness 
measurements (Rms) ~ 90 nm] over the scanned area (Figure 5A) when compared to the 
encapsulated core-shell particle system (Rms ~ 14 nm) (Figure 5B). This suggests particles are 
embedded within the core-shell for the encapsulated system and are dispersed throughout the 
matrix for the composite system; even on the outer surface. This further supports the possibility 
of localizing magnetic particles into the core-shell system along with chosen active molecules, 
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which could reduce leaching of particles and drugs from within the encapsulated assembly.  ζ-
potential for blank tristearin and final formulation particles were -4.9 and -22.9 mV, respectively. 
Even though tristearin is used in both particulate systems (neat and encapsulating shell 
morphologies), a clear difference in their respective ζ-potential values is observed. The final 
formulation, which hosts SPIONS, is responsible for the marked difference between the two 
values. Previous reports have shown iron oxide nanoparticles to possess ζ-potential values 
similar our core-shell composite system.
41
 As the value moves away from zero, greater 
dispersibility in expected arising due to enhanced electrostatic repulsive forces. Furthermore, this 
also suggests while the core shell system can encapsulate SPIONs, the impact of charge is still 
present. Encapsulation of SPIONs within variants of a modified polymeric shell have displayed 
indifferent ζ-potential values ranging from ~15.7 to -0.2 mV.
42
 This indicates SPIONs 
encapsulation material and excipient formulation also affects the dispersibility of overall 















Figure 5. Atomic Force Microscopy (AFM) of composite tristearin-SPIONs (A) and the final formulation 
of encapsulated SPIONs (B). 
 
Drug Release.  Core-shell micron and submicron particles have great potential as novel cancer 
therapies, both for improving the accumulation of drugs in tumor models and for minimizing 
their toxic side effects, for example SPIONs encapsulated in liposomes have proven effective for 
the treatment of breast cancer tumors.
43
 Genistein was selected as a model drug compound for 
drug release studies. It has recently demonstrated to inhibit the growth of human colon cancer 
cells and promoted apoptosis in a dose-dependent manner.
44
 The effects of genistein on other 
various types of cancer has been recently reviewed.
45
  
 The in vitro release profile of the composite tristearin-SPIONs and the final formulation of 
encapsulated SPIONs is shown in Figure 6. The composite tristearin-SPIONs demonstrated a 
burst followed by a slower second phase release profile. This can be attributed to the morphology 
of the composite particles, where the model drug (genistein) was dispersed throughout the 
particles and/or embedded on the surface. A burst release of 46% at 16 min was demonstrated. 
This second phase continued until the plateau point for the profile. The release of genistein at 
selected time points was 2 h (75%), 8 h (92%) and at 15 h (96%). A further 4% release was also 
demonstrated at 30 h (100%). 
In contrast, the encapsulated system demonstrated a triphasic release pattern. This has been 
demonstrated previously for other encapsulation techniques.
46
 The first phase of a typical 
triphasic release profile is generally a burst release, however, in this instance, an atypical gradual 
release of genistein (~ 20%) was observed up to 8 h. This is attributed to superficial matrix and 
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surface adsorbed genistein being released from the multimodal particles. The second phase of the 
triphasic release profile displayed a plateaued gradual release of genistein of ~40% up to 24 h. 
Partial hydrolysis and degradation of the tristearin matrix is thought to result in diffusion of 
genistein from the particles.
47
 A rapid release of genistein with 92% at 30 h is observed, most 
likely due to the total degradation of the particle matrix. The much slower drug release profile of 
the encapsulated particle may be useful for a more controlled release at the target site where the 
administration of a drug over a longer period of time may be more beneficial. Higuchi and 
Korsmeyer-Papas models were applied to the data obtained for the final particle formulation. The 
Higuchi model describes drug dissolution from different types of modified polymeric release 
dosage forms. The Higuchi model can be represented using equation 2.
48
 
                                                               𝑀𝑡 = 𝑘𝐻√𝑡                                     (Equation 2) 
Here, Mt is the quantity of cumulative drug released at time t, and kH is the Higuchi constant. 
The cumulative release of Genistein from all three samples was plotted as function of square root 
of time.  
Korsmeyer-Peppas model was used to investigate diffusive type mechanism from the 
polymeric matrix and shown in equation 3.  
        
𝑀𝑡
𝑀∞
=  𝑘 𝑡𝑛    (Equation 3) 
Here, Mt / M∞ is the proportion of genistein released at time, t.  k is the release rate constant 
and n is the release exponent; and is the factor which determines mechanism of drug release.  
The release exponent is derived using equation 4.  
                    
                                             log (
𝑀𝑡
𝑀∞
× 100) = 𝑛 log 𝑡 × log 𝑘                      (Equation 4) 
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The core-shell encapsulated SPIONs displayed an R
2   
value of 0.7725 and the n value was 
0.885 (for the Korsmeyer-Peppas Model). This indicated the mechanism was non-fickian 






Figure 6. In vitro release profile of composite tristearin-SPIONs (blue) and the encapsulated SPIONs 
(red). 
 
MTT Cytotoxicity Assay.  The cytotoxicity of particles depends on a number of factors, such as 
the composition of the material, the shape and size (particle morphology) and surface charge. For 
example, for non-phagocytic cells, increased toxicity is associated with the nanoparticle size 
when compared with larger, micron sized particles.
50,51
 This was also investigated for NPs 
smaller than 100 nm and this confirmed that smaller particles are often more toxic than larger 




 Although, no differences were observed 
when compared with silica particles with average size between 10-100 nm and 45 µm.
54
 Okuda-





addition, the toxicity exhibited by some particles could also be due to contamination, solubility 
and adsorption of compounds. This can be significantly affected by the particles concentration, 




The MTT [3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cell viability assay 
method was used to evaluate the cell viability in the presence of the NPs.
57
 The results of MTT 
assay for encapsulated SPIONs and tristearin NPs confirmed cellular toxicity only at the higher 
concentration of encapsulated particles (1 mg/mL) when compared to the control (HeLa cells + 
media). This toxicity could be due to the physiological effect of the particles or it could possibly 
be related to traces of the dichloromethane solvent used in their synthesis, which could 
theoretically reach toxic levels at higher particle concentrations. There were no significant 
differences observed in toxicity between the encapsulated SPIONs and tristearin NPs. The MTT 
assay of encapsulated SPIONs and the tristearin NPs with concentrations lower than 0.5 mg/mL 
showed low levels of toxicity, demonstrating cellular tolerance to the encapsulated SPIONs 




Figure 7. Cell viability assay data of tristearin NPs and the encapsulated SPIONs using HeLa cells 
(control being without NPs) after 24 h incubation of the cells (data were analyzed using one-way 
ANOVA with Bonferroni test * = p < 0.05 relative to control).   
 
Relaxivity measurements.  In order to examine the potential of the encapsulated SPIONs to act 
as a contrast agent for magnetic resonance imaging (MRI), transverse relaxation measurements 
were carried out. T2 was measured at 9.4 T (400 MHz) at ambient temperature. The transverse 
(𝑟2) relaxivity was determined using the following equation (5):    







) = 𝑟2  .  [SPIONs] 
 
Where T0 and T2 are the transverse relaxation times of water and of the samples with increasing 
SPIONs concentration.  











) was obtained (supporting Information, Figure 6). This can be compared to the 





Supporting Information, Figure S7), indicating increased 𝑟2 relaxivity. The low 𝑟2 relaxivity of 
the encapsulated SPIONs can be attributed to the coating layer (tristearin) preventing water 
molecules being within the range of the magnetic field generated by the SPIONS as well as the 
low SPIONs concentration into the particulate system (5 w/w % loading in 1 mg of collected 






Confocal Imaging and Cellular Uptake.  Surface characteristics (hydrophobicity and charge) 
are also important in the cellular uptake of materials for medical applications. While a positive 
charge seems to improve the efficacy of imaging and drug delivery, higher levels of cytotoxicity 
have also been reported for such species.
60
 The positive and negative charge effect on non-
phagocytic cells was probed to reveal that materials with a positively charged (cationic) surface, 





 It was also reported that positively charged gold particles, SPIONs, lipid 
particles, chitosan, polymeric and polystyrene particles are taken up by cells to a much greater 
extent compared to otherwise similar anionic particles.
63–67
  
Figure 9 shows uptake in HeLa cells of the encapsulated particles at different time points (1, 2 
and 4 h). Internalization of encapsulated SPIONs was observed in HeLa cell lines with only 4 h 
of incubation. Figure 9A shows HeLa cells after 24 h of incubation (control) before adding the 
encapsulated particles. Figure 9B shows the presence of particles and the adherence of 
encapsulated SPIONs to the surface of the HeLa cells. Cell uptake of encapsulated SPIONs and 
internalization in the cells
68
 was monitored with an image shown after 2 h (Figure 9C). Figure 
9D and 9E (at higher magnification) demonstrate cell uptake of large encapsulated particles after 
4 h of incubation. Figure 9F shows the presence of BODIPY fluorescent dye in the culture 
medium after 4 h. The internalization of the encapsulated SPIONs may also be related to the 
positively charged surface of the tristearin on the outer layer of the multi-modal particle system. 
Earlier reports suggest that the magnetic system can be improved by modification of iron oxide 






In this study, the mean size of the final formulation of particles was in the range 0.65-1.2 μm, 







electrospray process is a multi-variate process, which enables particle size scalability, based on 
process parameters (flow rate, applied voltage, formulation viscosity), component geometry (e.g. 
nozzle) and selected formulation excipients. Furthermore, the process is operational in a single 
step and the use of a filter or sieve could enable the collection of a desired particle size range. 
Cell internalization and external magnet localisation has been shown using the current 




Figure 9. Cell uptake and accumulation of the encapsulated SPIONs into HeLa cells incubated for 1, 2 
and 4 h. (A) Living HeLa cells visualized by Leica SP5 inverted confocal microscope, scale bar 20 μm; 
31 
 
(B) encapsulated SPIONs with BODIPY and HeLa cells incubated for 1 h, scale bar 10 μm; (C) cell 
uptake after 2 h of incubation, scale bar 30 μm; (D) cell uptake after 4 h of incubation, scale bar 100 μm; 
(E) 4 h incubation with higher magnification, scale bar 30 μm; (F) image showing presence of BODIPY 





SPIONs with a mean diameter of 10-15 nm were successfully encapsulated into a tristearin 
core-shell particle system along with a model drug (genistein), a BODIPY fluorescent dye and 
PEG in a single step under ambient conditions using a CO-ES process. Spectroscopic analytical 
methods confirmed the presence of excipients in the particle system. The encapsulated particles 
where much larger compared to the parent SPIONs and exhibited a mean size of ~ 0.65-1.2 µm 
with evidence of a layered structure based on electron microscopy images. This increased size 
was the likely result of agglomeration of SPIONs during the CO-ES process. It was found that 
the drug release profile of genistein from the encapsulated SPIONs was much slower over 30 h 
period compared composite particles prepared via the single method, and followed an atypical 
triphasic release. No significant toxicity was observed at 0.5 mg/mL loading for the encapsulated 
SPIONs based on an MTT assay.  Unsurprisingly, the encapsulated SPIONs displayed limited 𝑟2 
relaxivity due to the encapsulation preventing a rapid dephasing of the nuclear spins of water 
molecules, however, it may be anticipated that once the shell matrix of these particles breaks 
down, as is observed after 30 h, then relaxivity of the ‘free’ SPIONs would increase and 
therefore be more applicable for MRI imaging. Optical imaging studies of the encapsulated 
SPIONs show clear cellular uptake and internalization over a 4 h period.  This CO-ES approach 
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to the functionalization of SPIONs offers a straightforward and general way of coating inorganic 
nanoparticle materials with a polymeric drug loaded matrix. Investigations are currently 
underway to generate more monodisperse and smaller particles as well as diversifying the 




Schematic representations of SPION synthesis, UV-vis spectra of the synthesized SPIONS, 
mode mapping optimization information, FTIR of the raw materials and encapsulated SPIONs, 
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